These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31932108)

  • 1. Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
    Morgan RD; Banerjee S; Hall M; Clamp AR; Zhou C; Hasan J; Orbegoso C; Taylor S; Tugwood J; Lyon AR; Dive C; Rustin GJS; Jayson GC
    Gynecol Oncol; 2020 Mar; 156(3):545-551. PubMed ID: 31932108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
    Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
    JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
    Pignata S; Lorusso D; Scambia G; Sambataro D; Tamberi S; Cinieri S; Mosconi AM; Orditura M; Brandes AA; Arcangeli V; Panici PB; Pisano C; Cecere SC; Di Napoli M; Raspagliesi F; Maltese G; Salutari V; Ricci C; Daniele G; Piccirillo MC; Di Maio M; Gallo C; Perrone F;
    Lancet Oncol; 2015 May; 16(5):561-8. PubMed ID: 25882986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
    Sharma A; Singh M; Chauhan R; Malik PS; Khurana S; Mathur S; Kumar S; Sreenivas V; Kumar L
    Gynecol Oncol; 2021 Aug; 162(2):382-388. PubMed ID: 34088513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Monk BJ; Sill MW; Walker JL; Darus CJ; Sutton G; Tewari KS; Martin LP; Schilder JM; Coleman RL; Balkissoon J; Aghajanian C
    J Clin Oncol; 2016 Jul; 34(19):2279-86. PubMed ID: 27217446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
    Eichbaum M; Mayer C; Eickhoff R; Bischofs E; Gebauer G; Fehm T; Lenz F; Fricke HC; Solomayer E; Fersis N; Schmidt M; Wallwiener M; Schneeweiss A; Sohn C
    BMC Cancer; 2011 Oct; 11():453. PubMed ID: 22014006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
    Tewari KS; Sill MW; Coleman RL; Aghajanian C; Mannel R; DiSilvestro PA; Powell M; Randall LM; Farley J; Rubin SC; Monk BJ
    Gynecol Oncol; 2020 Oct; 159(1):79-87. PubMed ID: 32723679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
    Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
    Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
    Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
    Joly F; Fabbro M; Berton D; Lequesne J; Anota A; Puszkiel A; Floquet A; Vegas H; Bourgeois H; Bengrine Lefevre L; You B; Pommeret F; Lortholary A; Spaeth D; Hardy-Bessard AC; Abdeddaim C; Kaminsky-Forrett MC; Tod M; Kurtz JE; Del Piano F; Meunier J; Raban N; Alexandre J; Mouret-Reynier MA; Ray-Coquard I; Provansal Gross M; Brachet PE
    Gynecol Oncol; 2022 Sep; 166(3):389-396. PubMed ID: 35902297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
    Friedlander M; Hancock KC; Rischin D; Messing MJ; Stringer CA; Matthys GM; Ma B; Hodge JP; Lager JJ
    Gynecol Oncol; 2010 Oct; 119(1):32-7. PubMed ID: 20584542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
    Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
    Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
    Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
    Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
    O'Brien ME; Gaafar R; Hasan B; Menis J; Cufer T; Popat S; Woll PJ; Surmont V; Georgoulias V; Montes A; Blackhall F; Hennig I; Schmid-Bindert G; Baas P;
    Eur J Cancer; 2015 Aug; 51(12):1511-28. PubMed ID: 26074395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
    Duska LR; Petroni GR; Varhegyi N; Brown J; Jelovac D; Moore KN; McGuire WP; Darus C; Barroilhet LM; Secord AA
    Gynecol Oncol; 2020 Jun; 157(3):585-592. PubMed ID: 32247603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.
    Gulia S; Ghosh J; Bajpai J; Rath S; Maheshwari A; Shylasree TS; Deodhar K; Thakur M; Gupta S
    JCO Glob Oncol; 2020 Mar; 6():542-547. PubMed ID: 32228315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
    Moore KN; Birrer MJ; Marsters J; Wang Y; Choi Y; Royer-Joo S; Lemahieu V; Armstrong K; Cordova J; Samineni D; Schuth E; Vaze A; Maslyar D; Humke EW; Hamilton EP; Liu JF
    Gynecol Oncol; 2020 Sep; 158(3):631-639. PubMed ID: 32534811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
    Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.